ArticleEye (London, England)2019
Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis.
Raymond S DouglasPubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
30 papers cite it
this papertrialcites it